Lowest Price Guaranteed
Slides
240
Last Updated
July 2026
View Count
26774
The global anti-obesity drugs market, valued at USD 28.2 billion in 2025, is projected to reach USD 45.1 billion in 2026 and USD 106.5 billion by 2035, representing a CAGR of 10.0% during the forecast period 2026 to 2035.
To learn more about this report, request a free sample copy
Anti-obesity drugs, also known as weight loss drugs, encompass a range of pharmaceutical treatments designed to assist individuals in managing obesity and related conditions. These drugs aim to promote weight loss by influencing appetite regulation, fat absorption, and metabolism.
Notably, approximately 40% of adults in the US are classified as obese, with a body mass index (BMI) of 30 or higher, underscoring the substantial potential for growth in this domain. With rising global obesity rates and increased awareness of the associated health risks, including diabetes, cardiovascular diseases, and certain cancers, the demand for effective anti-obesity drugs has surged. It is worth mentioning that, in recent years, several new anti-obesity drugs have received regulatory approval, expanding options for patients and providing alternatives to bariatric surgery.
Anti-obesity drugs provide healthcare professionals with valuable tools to complement lifestyle interventions, such as diet and exercise. They play a critical role in enhancing weight loss outcomes, particularly for patients with significant obesity-related comorbidities. Further, these drugs contribute to improved quality of life and can lead to reduced healthcare costs by preventing obesity-related complications.
Advancements in drug formulation and delivery systems, along with the integration of novel compounds, have led to the emergence of more effective and safer anti-obesity medications. The increasing focus on personalized medicine and pharmacogenomics further enhances the potential for tailored treatments that address individual patient needs. Additionally, the surge in telehealth services and digital therapeutics applications is facilitating better patient engagement and adherence to treatment regimens.
Further, as pharmaceutical companies and digital healthcare platforms strive to capture market share in this rapidly expanding sector, the anti-obesity domain is experiencing a wave of strategic acquisitions and mergers. These acquisitions are accelerating market growth by consolidating expertise, expanding geographic reach, and gaining access to established patient networks. A notable example is Voy's acquisition of EarlyFit in May 2026, where London-headquartered digital healthcare company Voy acquired a 100% stake in New Delhi-based EarlyFit, an online weight-loss platform, to enter India's obesity care market and serve 150 million obese Indians.
| Drug | Developer | Year of Establishment | Headquarters | Status of Development | Mechanism of Action |
| Tirzepatide (Zepbound/Mounjaro) | Eli Lilly | 1876 | Indianapolis, USA | Approved | GLP-1 & GIP Agonist |
| Semaglutide (Wegovy) | Novo Nordisk | 1923 | Bagsværd, Denmark | Approved | GLP-1 Agonist |
| CagriSema | Novo Nordisk | 1923 | Bagsværd, Denmark | Phase III | GLP-1 & Amylin Agonist |
| Orforglipron | Eli Lilly | 1876 | Indianapolis, USA | Phase III | GLP-1 Agonist |
| ECC5004 | Eccogene | 2018 | China | Phase II | GLP-1 Agonist |
Based on the research, we have segmented the Anti-Obesity Drugs Market into type of molecule, type of drug, active compound used, mechanism of action, type of agonist, action pathway, route of administration, distribution channel, key geographical regions, sales forecast and key players.
By Type of Molecule
By Type of Drug
By Active Compound Used
By Mechanism of Action
By Type of Agonist
By Action Pathway
By Route of Administration
By Distribution Channel
By Key Geographical Regions
The anti-obesity domain is witnessing a significant shift from injectable GLP-1 therapies to next-generation oral therapies, driven by patient preference for convenient, needle-free administration with improved scalability and reduced storage requirements.
While injectable GLP-1 drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) have achieved remarkable 15–25% weight loss, oral formulations eliminate injection barriers, reduce cold storage needs, and lower distribution costs. This makes the treatment more accessible to patients who are reluctant to use injections, or in regions with limited healthcare infrastructure.
A significant example of this transformation is the collaboration between OPKO Health and Entera Bio to advance OPK-88006, the first oral dual GLP-1/glucagon agonist peptide in a once-daily tablet format for obesity, metabolic, and fibrotic disorders.
Driven by the broad applications of anti-obesity drugs across weight management, cardiovascular disease prevention, diabetes treatment, and other metabolic conditions, the anti-obesity drugs market is poised to grow significantly in the near future.
Lars Fruergaard Jorgensen (Former Chief Executive Officer, Novo Nordisk), stated that, “There's more than 100 million people living with obesity and that number is growing. So far, we are only serving around 1 million patients. We have access to around 50 million patients, and we have to restrict starter doses to make sure that those who start treatment can – up to the maintenance doses.”
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following third-party discussions:
This segment highlights the distribution of market value for anti-obesity drugs across various types of molecules, such as biologics and small molecules.
Currently, the biologics subsegment captures the majority (close to 55%) of the anti-obesity drugs market share. This is because biologics target underlying biological pathways associated with obesity through gut-brain hormone regulation (GLP-1, GIP, glucagon receptors), offering more comprehensive metabolic benefits beyond weight loss; such benefits include cardiovascular risk reduction, kidney disease protection, and diabetes remission.
Additionally, the pipeline momentum heavily favors biologics, with the majority of anti-obesity drugs in clinical trials being GLP-1-based biologics. This positions biologics to reshape the market as these newer, more effective formulations launch and capture larger patient populations. Further, due to such advantages, the market for biologics segment is anticipated to grow at a faster pace during the forecast period.
This segment highlights the distribution of market value for anti-obesity drugs across various types of drugs, such as prescription drugs and OTC drugs.
Currently, the prescription drugs subsegment captures the majority of the anti-obesity drugs market share. This can be attributed to their greater efficacy and clinically proven weight-loss outcomes when compared to over-the-counter products. Further, these anti-obesity medications undergo rigorous clinical trials and regulatory review, providing physicians and patients with confidence in their safety and effectiveness.
Additionally, owing to the increasing consumer preference for convenient, accessible, and cost-effective weight management solutions, the market for OTC drugs is expected to grow at a faster pace during the forecast period. Notably, unlike prescription medications, OTC products can be purchased without a physician's consultation, making them attractive to individuals seeking early intervention for weight control or those with mild to moderate weight concerns.
This segment highlights the distribution of market value for anti-obesity drugs across various types of active compounds, such as tirzepatide, semaglutide, retatrutide, survodutide, cagrilintide and semaglutide, orforglipron, liraglutide and other active compounds.
Currently, the tirzepatide segment occupies the highest market share (more than 45%). This can be attributed to its exceptional efficacy in promoting weight loss when compared to earlier obesity therapies. Further, as a dual GIP and GLP-1 receptor agonist, tirzepatide delivers superior reductions in body weight by simultaneously regulating appetite, food intake, insulin secretion, and energy metabolism. Clinical studies have also demonstrated substantial and sustained weight-loss outcomes, making it one of the most effective pharmacological treatments available for obesity management.
The market for other active compounds is expected to grow at a significant pace during the forecast period owing to the increasing diversification of the obesity treatment landscape and the advancement of novel therapeutic mechanisms. Notably, pharmaceutical companies are actively developing next-generation anti-obesity agents that target multiple metabolic pathways, improve efficacy, enhance tolerability, and offer more convenient administration options. Furthermore, as healthcare providers seek alternatives for patients who may not respond adequately to existing therapies or experience adverse effects, the demand for innovative obesity treatments is likely to increase.
This segment highlights the distribution of market value for anti-obesity drugs across various mechanisms of action, such as GLP-1 agonists, GLP-1 agonists / GIP agonists, GLP-1 agonists / GCGR agonists, GLP-1 agonists / GCGR agonists / GIP agonists, GLP-1 agonists / amylin analogues and other mechanisms of action.
Currently, the GLP-1 agonists dominate the market due to their well-established mechanism of action, to improve glycemic control, thereby promoting significant weight loss. Their ability to enhance satiety and reduce appetite is a foundation in obesity treatment.
However, the introduction of dual GLP-1 and GCGR agonists is poised to reshape the landscape by growing at a comparatively higher CAGR due to their ability to target multiple metabolic pathways. According to clinical studies, dual agonists can yield greater weight loss and improved metabolic profiles compared to GLP-1 agonists alone. As healthcare providers seek more effective solutions for obesity management, the enhanced efficacy of GLP-1 and GCGR agonists is expected to drive their adoption and foster rapid market growth.
This segment highlights the distribution of market value for anti-obesity drugs across various types of agonists, such as single-agonists, dual-agonists and tri-agonists.
Single agonists currently capture the maximum anti-obesity drugs market share due to their simplicity and ease of use, which facilitates patient adherence. These medications have a long-standing history of clinical success, allowing healthcare providers to confidently prescribe them based on extensive data.
The tri-agonists segment is expected to grow at a significant pace during the forecast period due to its potential to deliver superior weight-loss outcomes by simultaneously targeting multiple metabolic pathways. Growing clinical evidence demonstrating their promising efficacy and metabolic benefits has increased interest among pharmaceutical companies, healthcare providers, and patients. Furthermore, the strong pipeline of tri-agonist candidates in clinical development, rising investments in next-generation obesity treatments, and the increasing demand for more effective long-term weight management solutions are expected to drive substantial growth of this segment.
This segment highlights the distribution of market value for anti-obesity drugs across various action pathways, such as centrally acting, peripherally acting, and centrally and peripherally acting pathways.
Currently, the centrally acting drugs segment captures the highest anti-obesity drugs market share and is expected to dominate the market during the forecast period. This can be attributed to their effectiveness in modulating appetite and energy expenditure through direct interactions with the central nervous system. These mechanisms facilitate significant weight loss by altering hunger signals and enhancing satiety, making them a favoured choice among both clinicians and patients. Additionally, centrally acting agents have a well-established safety profile, which further solidifies their position in clinical practice.
Additionally, the reliance on centrally acting pathways is likely to remain strong, as they provide a comprehensive approach to managing weight. Despite ongoing research into alternative pathways, the robust clinical evidence supporting the efficacy of centrally acting agents ensures their continued dominance in the market. Consequently, while new treatments may emerge, the trend towards centrally acting pathways is expected to persist, reflecting their fundamental role in obesity management.
This segment highlights the distribution of market value for anti-obesity drugs across various routes of administration, such as oral and parenteral.
Currently, the parenteral route captures the majority share in the market owing to its rapid onset of action and higher bioavailability compared to oral formulations. Parenteral delivery enables medications to bypass the gastrointestinal tract, reducing variability in absorption and enhancing therapeutic effectiveness. It is advantageous for agents that require precise dosing and consistent plasma levels to achieve optimal weight loss outcomes.
However, the market for oral route is expected to grow at a faster pace during the forecast period. This is due to its convenience, ease of use, and higher patient acceptance when compared to injectable therapies. Further, oral medications eliminate the need for injections, reducing treatment burden and improving adherence among patients requiring long-term weight management. Additionally, oral drugs are generally easier to distribute, store, and prescribe, making them more accessible across a broader patient population.
This segment highlights the distribution of market value for anti-obesity drugs across various distribution channels, such as hospital pharmacy, and retail and online pharmacy.
Currently, retail and online pharmacies capture the majority share in the market owing to the widespread accessibility, convenience, and ability to cater to a large patient population requiring long-term weight management therapies. These distribution channels provide easy access to both prescription and over-the-counter anti-obesity medications, enabling patients to refill prescriptions conveniently and maintain treatment adherence.
However, as the use of advanced anti-obesity therapies, including injectable GLP-1 receptor agonists, dual agonists, and emerging tri-agonists, continues to rise, more patients are seeking treatment through specialized obesity clinics and hospital settings. Hospital pharmacies play a critical role in dispensing high-cost prescription medications, managing complex treatment regimens, and ensuring proper patient monitoring and follow-up. Furthermore, the growing number of obesity-related comorbidities, increasing hospital-based weight management programs, and expanding reimbursement support for medically supervised obesity treatment are expected to drive the growth of the hospital pharmacy segment over the forecast period.
According to our projections, North America is likely to capture the majority (~65%) of the anti-obesity drugs market share in 2026. This can be attributed to a high prevalence of obesity and related comorbidities, driving the demand for effective treatment options. Additionally, the region benefits from advanced healthcare infrastructure, significant investment in pharmaceutical research, and robust regulatory frameworks that facilitate the development and approval of new therapies.
The market in Asia-Pacific is likely to grow at the highest CAGR during the forecast period. This is due to the rapidly increasing prevalence of obesity and overweight populations across major countries such as China, India, Japan, and South Korea. Urbanization, sedentary lifestyles, changing dietary habits, and rising consumption of calorie-dense foods have significantly contributed to the growing obesity burden in the region. In addition, increasing healthcare expenditure, improving access to advanced obesity treatments, and growing awareness regarding the health risks associated with obesity are supporting market expansion.
| Key Report Attribute | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | Till 2035 | |
| Market Size 2026 | $ 45.1 Billion | |
| Market Size 2035 | $ 106.5 Billion | |
| CAGR (Till 2035) | 10.0% | |
| Segments Covered |
|
|
| Key Players |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
Available | |